Y Intercept Hong Kong Ltd Buys New Stake in Icon Plc $ICLR

Y Intercept Hong Kong Ltd bought a new position in Icon Plc (NASDAQ:ICLR) during the 3rd quarter, Holdings Channel reports. The fund bought 7,668 shares of the medical research company’s stock, valued at approximately $1,342,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ICLR. New Wave Wealth Advisors LLC bought a new stake in Icon during the third quarter valued at about $246,000. Hudson Edge Investment Partners Inc. lifted its position in shares of Icon by 12.4% during the 3rd quarter. Hudson Edge Investment Partners Inc. now owns 200,739 shares of the medical research company’s stock worth $35,129,000 after purchasing an additional 22,164 shares during the last quarter. Osborne Partners Capital Management LLC boosted its stake in Icon by 2.7% during the 3rd quarter. Osborne Partners Capital Management LLC now owns 51,590 shares of the medical research company’s stock valued at $9,028,000 after purchasing an additional 1,342 shares during the period. Fisher Funds Management LTD grew its holdings in Icon by 11.5% in the 3rd quarter. Fisher Funds Management LTD now owns 431,083 shares of the medical research company’s stock valued at $75,440,000 after buying an additional 44,390 shares during the last quarter. Finally, Arkadios Wealth Advisors increased its position in Icon by 35.8% in the 3rd quarter. Arkadios Wealth Advisors now owns 13,832 shares of the medical research company’s stock worth $2,421,000 after buying an additional 3,650 shares during the period. Institutional investors and hedge funds own 95.61% of the company’s stock.

Analyst Upgrades and Downgrades

ICLR has been the topic of several research analyst reports. Mizuho set a $216.00 price objective on shares of Icon in a research note on Friday, January 9th. Leerink Partners reissued an “outperform” rating on shares of Icon in a report on Monday, January 5th. BMO Capital Markets began coverage on shares of Icon in a research report on Thursday, November 13th. They issued a “market perform” rating and a $175.00 price target on the stock. UBS Group set a $220.00 price objective on shares of Icon in a research report on Friday, October 24th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Icon in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and eleven have given a Hold rating to the stock. Based on data from MarketBeat, Icon has an average rating of “Hold” and an average target price of $200.60.

Icon Stock Performance

NASDAQ:ICLR opened at $180.25 on Friday. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31. The firm has a 50-day moving average price of $183.96 and a 200 day moving average price of $176.40. The firm has a market capitalization of $14.56 billion, a PE ratio of 24.39, a price-to-earnings-growth ratio of 3.93 and a beta of 1.26. Icon Plc has a 12-month low of $125.10 and a 12-month high of $211.00.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.